Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Net Income towards Common Stockholders (2016 - 2025)

Vistagen Therapeutics' Net Income towards Common Stockholders history spans 13 years, with the latest figure at -$18.9 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 34.14% year-over-year to -$18.9 million; the TTM value through Dec 2025 reached -$67.0 million, down 85.87%, while the annual FY2025 figure was -$51.4 million, 75.12% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$18.9 million at Vistagen Therapeutics, up from -$19.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.7 million in Q1 2024 and bottomed at -$29.6 million in Q1 2021.
  • The 4-year median for Net Income towards Common Stockholders is -$13.0 million (2024), against an average of -$12.3 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 34.14% in 2025 against a maximum downside of 896.86% in 2025.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at -$10.7 million in 2021, then skyrocketed by 40.89% to -$6.4 million in 2023, then tumbled by 121.87% to -$14.1 million in 2024, then crashed by 34.14% to -$18.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Net Income towards Common Stockholders are -$18.9 million (Q4 2025), -$19.4 million (Q3 2025), and -$15.1 million (Q2 2025).